Ketamine does relax airway smooth muscle in the lab, and it has been used for decades as a bronchodilator of last resort in emergency and critical care settings. Yet the clinical trial evidence in actual patients with severe asthma is surprisingly underwhelming. The disconnect between ketamine’s clear pharmacological effect on isolated tissue and its inconsistent performance in human trials is one of the more frustrating puzzles in acute airway management, and the answer has a lot to do with how the drug works at a cellular level versus what happens when a real patient is already receiving aggressive standard therapy.
How Ketamine Relaxes Airway Smooth Muscle
Ketamine is best known as a dissociative anesthetic that blocks NMDA receptors in the brain. You might expect its bronchodilatory effect to work through the same receptor, but it doesn’t. Research on tracheal smooth muscle contracted with histamine found that ketamine’s relaxation effect persisted even when other NMDA-blocking drugs had no impact, and that the NMDA agonist itself couldn’t reverse ketamine’s airway effects. The conclusion was that ketamine relaxes contracted airways through a pathway independent of NMDA receptors, likely by interfering with the calcium signaling that muscles need to stay contracted.1PubMed Central. The role of the N-methyl-D-aspartic acid receptor in the relaxant effect of ketamine on tracheal smooth muscle
The calcium story is well characterized. When airway smooth muscle contracts, calcium floods into cells through voltage-dependent channels and keeps the muscle clenched. Studies on canine airway tissue showed that ketamine caused a concentration-dependent decrease in both the force of contraction and intracellular calcium levels, and at higher concentrations it directly blocked calcium from entering the cells.2Anesthesiology. Calcium concentration-dependent mechanisms through which ketamine relaxes canine airway smooth muscle Separate work on porcine tracheal cells confirmed that ketamine inhibits voltage-dependent calcium channels in airway smooth muscle, essentially cutting off the calcium supply that sustains a bronchospasm.3Anesthesiology. Inhibitory Effects of Thiopental, Ketamine, and Propofol on Voltage-dependent Calcium sup 2+ Channels in Porcine Tracheal Smooth Muscle Cells
On top of this direct muscle relaxation, ketamine triggers the release of catecholamines, the body’s own adrenaline-like chemicals. This sympathomimetic effect raises blood pressure and heart rate, but it also contributes to airway dilation because catecholamines relax bronchial smooth muscle. Animal studies using direct visualization of airways with a tiny fiberoptic scope showed that ketamine reversed histamine-induced bronchoconstriction in vivo, and a sub-threshold dose of ketamine significantly boosted the bronchodilating effect of adrenaline.4PubMed. In vivo spasmolytic effect of ketamine and adrenaline on histamine-induced airway constriction. Direct visualization method with a superfine fibreoptic bronchoscope So there are at least two pharmacological routes by which ketamine opens constricted airways: a direct calcium-blocking action on smooth muscle and an indirect catecholamine-mediated dilation.
Why the Lab Results Don’t Translate Neatly to Clinical Trials
Given all that pharmacology, you’d expect ketamine to produce dramatic improvements in people having severe asthma attacks. The clinical reality is more complicated. The problem isn’t that ketamine doesn’t relax airways at all in living humans. It’s that by the time a patient is sick enough for a clinician to consider ketamine, they’ve typically already received aggressive treatment with nebulized beta-agonists, systemic corticosteroids, and often intravenous magnesium. Adding ketamine on top of all that standard therapy has repeatedly failed to show a clear additional benefit in controlled trials.
One of the most cited studies enrolled 53 adults with acute asthma exacerbations whose peak flow was below 40 percent of predicted after three rounds of albuterol. Half received low-dose intravenous ketamine and half received placebo, on top of continuous nebulized albuterol and intravenous steroids. Both groups improved significantly over the study period, but there was no difference between the ketamine and placebo groups. The investigators initially used a 0.2 mg/kg bolus but had to drop it to 0.1 mg/kg after the first nine patients because of unpleasant dissociative reactions.5PubMed Central. Ketamine in status asthmaticus: A review Another randomized, double-blind trial in the emergency department reached the same conclusion: at doses low enough to avoid significant psychological side effects, intravenous ketamine didn’t add measurable bronchodilation beyond standard therapy.6PubMed. Randomized, double-blind, placebo-controlled trial of intravenous ketamine in acute asthma
Not every trial has been negative. A randomized study testing slightly higher single doses found that ketamine at 0.4 and 0.5 mg/kg significantly increased peak expiratory flow compared to placebo, while the 0.3 mg/kg dose did not differ from placebo.7PubMed Central. The Effect of Low-Dose Ketamine in Treating Acute Asthma Attack; a Randomized Clinical Trial This dose-response pattern hints that the negative trials may have been using doses on the low end of what’s needed to produce a measurable clinical effect, but higher doses bring more side effects, which is the central trade-off with ketamine in conscious patients.
What the Systematic Reviews Say
When researchers have tried to pool the available trial data, the picture stays murky. A systematic review of prospective studies on ketamine in refractory severe asthma exacerbations found an absence of clear benefit, along with signals pointing toward side effects.8PubMed Central. Use of ketamine in patients with refractory severe asthma exacerbations: systematic review of prospective studies A separate meta-analysis that pooled ketamine versus placebo data found a trend favoring ketamine, with roughly an 18 percent improvement in peak expiratory flow, but this did not reach conventional statistical significance. There was no meaningful heterogeneity across the included studies, meaning the trials were at least consistently showing the same modest, non-significant trend rather than wildly contradicting each other.9The Journal of Medicine, Law & Public Health. Ketamine for Adults with Severe Asthma Exacerbation: A Systematic Review and Meta-analysis
The frustration here is palpable in the literature. Researchers acknowledge that the existing trials are small, that dosing varies widely, and that most enrolled patients who were already getting maximal standard therapy. Detecting an incremental benefit on top of aggressive treatment requires large sample sizes, and no one has run a trial large enough to definitively settle the question. The evidence doesn’t say ketamine is useless for airways. It says we can’t prove it helps enough beyond standard therapy to justify routine use based on current data.
Pediatric Evidence
The story in children is similar but carries different weight because kids with status asthmaticus have fewer medication options and can deteriorate faster. A randomized trial in a pediatric emergency department tested ketamine at 0.2 mg/kg followed by a 0.5 mg/kg per hour infusion for two hours in children with moderately severe asthma. It found no incremental benefit over standard therapy.10PubMed. The efficacy of ketamine in pediatric emergency department patients who present with acute severe asthma But observational data from smaller uncontrolled case series tell a different story. In one emergency department study, ten children with status asthmaticus who had not responded to conventional treatment received ketamine at a higher loading dose of 1 mg/kg followed by a continuous infusion. Their asthma severity indices improved with the addition of ketamine.11PubMed. Emergency department use of ketamine in pediatric status asthmaticus
A review of ketamine continuous infusions in critically ill children found that the majority of reports involved kids receiving ketamine specifically for bronchospasm that hadn’t responded to standard treatment. Doses ranged from 0.2 to 3.6 mg/kg per hour, substantially higher than what was used in the negative randomized trials. About 11 percent of patients experienced adverse events, but only about 4 percent had emergence phenomena, the vivid dreams and agitation that most clinicians worry about with ketamine.12PubMed. Ketamine Continuous Infusions in Critically Ill Infants and Children The pattern across the pediatric literature is that ketamine tends to show up in the sickest patients as a last-ditch intervention, and in that context the observational data is generally favorable even though controlled trials in less severe cases are not.
Nebulized Ketamine as a Delivery Route
Because ketamine’s airway effect involves direct smooth muscle relaxation, delivering the drug straight to the airways through nebulization is an appealing idea. A case report described a 26-month-old girl with a severe asthma exacerbation who was failing standard treatment and heading toward mechanical ventilation. Nebulized ketamine was administered and the child improved enough to avoid intubation.13PubMed. Nebulized ketamine to avoid mechanical ventilation in a pediatric patient with severe asthma exacerbation A randomized trial comparing nebulized ketamine against intravenous magnesium sulfate in corticosteroid-resistant asthma found that the ketamine group had roughly double the improvement in peak flow compared to the magnesium group, though the difference didn’t reach statistical significance in the small sample.14PubMed Central. The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial
Nebulized delivery has the theoretical advantage of concentrating the drug right where the bronchospasm is happening, potentially achieving local smooth muscle relaxation with lower systemic doses and fewer dissociative side effects. The evidence base is still thin, mostly case reports and small trials, but it’s an active area of interest, particularly for patients who are too sick for the side effects of intravenous ketamine to be acceptable but not quite sick enough to intubate.
The Secretion Problem
One reason clinicians think twice before using ketamine for airway issues is that it stimulates salivary and bronchial secretions. In a patient whose airways are already narrowed and inflamed, adding a layer of mucus is counterproductive. This effect is real and clinically significant. A randomized trial of intramuscular ketamine sedation in children found that about 31 percent of those who received placebo instead of atropine developed hypersalivation, compared to about 11 percent of those pretreated with atropine.15PubMed Central. Is atropine needed with ketamine sedation? A prospective, randomised, double blind study That’s a high baseline rate of excess salivation, and in a patient with severe bronchospasm, the additional secretions can be genuinely dangerous.
In practice, when ketamine is used for refractory asthma, clinicians often co-administer an antisialagogue like glycopyrrolate or atropine to dry up secretions. This adds complexity to what is already a high-acuity situation, but it’s become standard practice when ketamine is deployed for airway indications. The secretion issue doesn’t negate ketamine’s bronchodilatory properties, but it does partially offset them and explains some of the clinical reluctance to reach for the drug.
When Clinicians Actually Use It
Despite the ambiguous trial data, ketamine occupies a well-established niche in emergency and critical care. There are a few specific scenarios where it shows up consistently.
The clearest is intubation of the asthmatic patient. When someone with severe asthma needs to be placed on a ventilator, the induction agent matters. Most anesthetics depress respiratory drive and can worsen bronchospasm during the intubation itself. Ketamine preserves respiratory drive and laryngeal reflexes better than alternatives like propofol, which reduces the risk of apnea and aspiration during the procedure. It also maintains blood pressure, which is important in asthmatic patients who may already be hemodynamically stressed from air trapping. For these reasons ketamine is widely considered the induction agent of choice when intubating a patient with active bronchospasm, even by clinicians who are skeptical of its use as a standalone bronchodilator.
The second scenario is the patient in refractory status asthmaticus who is already intubated and not improving. A retrospective case series of six intubated adults with status asthmaticus who received intravenous ketamine boluses followed by infusions found that their blood gases improved substantially: the average carbon dioxide level dropped from about 98 to 58 mmHg, and pH improved from a mean of 7.05 to 7.21.16CHEST. Ketamine in Status Asthmaticus: A Review These were critically ill patients on the verge of cardiopulmonary collapse, and at that level of severity, any pharmacological intervention that might help is worth trying. This is the context where most of the favorable case reports and case series originate: the sickest patients for whom conventional therapy has already failed.
Esketamine, the S-enantiomer of ketamine, has also attracted interest. It carries the same bronchodilatory and blood-pressure-supporting properties, and has been explored as an analgesic option for mechanically ventilated patients with acute respiratory distress syndrome, where its airway-friendly profile offers a theoretical edge over opioid-based sedation.17BMC Anesthesiology. Comparison of the effects of esketamine/midazolam and remifentanil/midazolam on respiratory mechanics in mechanically ventilated patients with acute respiratory distress syndrome
Beyond Bronchodilation: Anti-Inflammatory Effects
An emerging thread in the research is whether ketamine might do more than just relax airway muscle in the short term. Animal studies have looked at whether inhaled ketamine can influence the structural changes that happen in chronically inflamed airways. In a mouse model of asthma, ketamine inhalation suppressed a process called epithelial-mesenchymal transition, a cellular shift associated with airway remodeling and thickening. Markers of this transition were elevated in asthmatic mice and reversed after ketamine treatment.18PubMed Central. Ketamine Inhalation Ameliorates Ovalbumin-Induced Murine Asthma by Suppressing the Epithelial-Mesenchymal Transition
This is very early-stage work and it’s a long road from mouse models to clinical practice. But it does raise the question of whether ketamine’s usefulness in airway disease might extend beyond acute smooth muscle relaxation. If the drug has genuine anti-remodeling properties, that could have implications for chronic severe asthma management down the line. For now, this is a research lead rather than a treatment option, but it’s worth knowing about because it suggests that the story of ketamine and airways isn’t finished being written.
Preserving Respiratory Drive and Airway Reflexes
One of ketamine’s most distinctive features, and arguably its greatest practical advantage in airway management, is that it doesn’t suppress breathing the way most other sedatives and anesthetics do. At typical clinical doses, patients continue to breathe on their own, maintain their cough reflex, and keep their airway tone intact. This makes ketamine especially valuable in scenarios where sedation is needed but the clinician doesn’t want to commit to full airway management. A review of ketamine’s respiratory profile noted that it preserves airway tone and the laryngopharyngeal reflex while providing bronchodilation, though it cautioned that large intravenous boluses can cause transient apnea and that airway reflexes in infants are unpredictable.19PubMed Central. Comeback of ketamine: resurfacing facts and dispelling myths
This profile is why ketamine ends up being used in procedural sedation for children in emergency departments, in prehospital settings where intubation capabilities are limited, and in austere environments where monitoring equipment is sparse. The airway-protective properties are separate from and arguably more clinically important than the bronchodilatory effect. A drug that keeps a patient breathing, maintains muscle tone in the upper airway, and also happens to relax the lower airways is a uniquely useful tool, even if its bronchodilation alone isn’t powerful enough to show up in placebo-controlled trials.
Veterinary Parallels
Ketamine’s airway profile isn’t limited to human medicine. In veterinary anesthesia, the drug is valued for the same combination of respiratory preservation and bronchodilation. Compared to other induction agents like propofol and alfaxalone, ketamine preserves respiratory drive and laryngeal reflexes, reducing the risk of apnea and aspiration during anesthesia, and can promote bronchodilation.20Angell Animal Medical Center. Ketamine Revisited: Are There Any Absolute Contraindications? This is relevant because much of the original pharmacological work on ketamine’s airway effects was done in animal models using canine and porcine tissue, and veterinary clinical experience adds another source of real-world data on how the drug behaves in living airways. Dogs and cats with reactive airway disease or upper airway obstruction are routinely anesthetized with ketamine for precisely the same reasons it’s chosen for asthmatic humans: it’s the induction agent least likely to make the airway situation worse.
The consistency of this profile across species, from isolated smooth muscle strips in the lab, to mouse asthma models, to dogs and cats in veterinary clinics, to critically ill humans in the ICU, reinforces that ketamine genuinely does something meaningful to airways. The open question has never been whether the pharmacology is real. It’s whether that pharmacology translates to a clinically detectable benefit in humans who are already receiving potent bronchodilators by other routes.